Ex­clu­sive: Af­ter four decades, one re­searcher's rad­i­cal HIV cure fi­nal­ly gets its shot

5 years ago
People
Startups

No­var­tis part­ners with the Gates Foun­da­tion on one of the Holy Grails in gene ther­a­py: a sim­ple, in vi­vo ap­proach to ...

5 years ago
Deals

Pi­o­neer­ing re­gen­er­a­tive med sci­en­tist Lau­ra Nikla­son takes her com­pa­ny pub­lic in the lat­est big SPAC deal. And that ...

5 years ago
Financing

Weeks af­ter drop­ping big re­sponse da­ta, Am­gen lines up pri­or­i­ty re­view for KRAS hope­ful so­tora­sib in NSCLC

5 years ago
Pharma
FDA+

No­var­tis' En­tresto, fac­ing a big come­back in hard-to-treat heart fail­ure pa­tients, scores FDA nod af­ter ad­comm ...

5 years ago
Pharma
FDA+

Sesen Bio, af­ter years on the edge of ir­rel­e­van­cy, scores speedy re­view for long ges­tat­ing blad­der can­cer pro­gram

5 years ago
FDA+

Cel­lec­tis signs $760M mile­stone deal with NK up­start; Im­muno­core brings on As­traZeneca vet to shep­herd bis­pe­cif­ic ...

5 years ago
News Briefing

'I’m not try­ing to re­build an ego': Neil Wood­ford ap­peals to pro­fes­sion­als for his come­back biotech fund

5 years ago
People
Financing

As­traZeneca's Pas­cal So­ri­ot picks up $21.5M pay pack­age in 2020, a big haul in year marked by Covid-19 shot ...

5 years ago
People

Up­dat­ed: Cor­texyme's un­ortho­dox Alzheimer's ap­proach tripped up by FDA hold

5 years ago
FDA+

Blue­bird hits the brakes on Lenti­Glo­bin stud­ies, Zyn­te­glo mar­ket­ing af­ter AML, myelodys­plas­tic syn­drome cas­es spur ...

5 years ago
R&D
Cell/Gene Tx

Khosla bets big on SPAC boom, rais­ing $1.2 bil­lion for 3 vague­ly tar­get­ed blank-check com­pa­nies

5 years ago
Financing

Covid-19 roundup: North Ko­rea at­tempt­ed to steal Pfiz­er vac­cine tech; WHO OKs As­traZeneca shot de­spite South Africa ...

5 years ago
Coronavirus

In a rare le­gal de­feat, Bris­tol My­ers Squibb and Sanofi fined $834M for 'de­cep­tive mar­ket­ing' on best-sell­ing blood ...

5 years ago
Pharma

Francesco De Ru­ber­tis makes his lega­cy play, re­cruit­ing star ex­ecs and rolling up 10 biotech star­tups in­to a $250M ...

5 years ago
Startups

An­oth­er Keytru­da com­bo tops stan­dard of care in ad­vanced kid­ney can­cer, pos­ing new test for Bris­tol's I/O med

5 years ago
Pharma

Astel­las, Seagen pave the way for Pad­cev's glob­al roll­out with full con­fir­ma­to­ry da­ta for urothe­lial can­cer in hand

5 years ago
Pharma
FDA+

Take­da suc­ceeds where oth­er phar­mas have failed with PhI­II win for cy­tomegalovirus castoff marib­avir

5 years ago
R&D

Ex-Vi­vid­ion chief Diego Mi­ralles finds 'dream team' at stealthy Flag­ship port­fo­lio com­pa­ny; Astel­las looks in­ward to ...

5 years ago
Peer Review

Mys­tery in­vestors back a new NASH ap­proach; GSK an­tibi­otics sale trig­gers lay­off fears

5 years ago
News Briefing

A pair of biotechs pre­pares to hit Nas­daq, as to­tal 2021 IPO raise quick­ly ap­proach­es $3B

5 years ago
Financing

FDA slaps Flori­da's Al­lay Phar­ma­ceu­ti­cals with warn­ing let­ter over vague re­spons­es to drug po­ten­cy is­sues

5 years ago
FDA+
Manufacturing

Gy­ro­scope posts ear­ly win with gene ther­a­py for AMD, giv­ing hope for its im­mune com­ple­ment sys­tem tar­get

5 years ago
R&D

De­nali un­veil proof-of-con­cept da­ta for brain de­liv­ery tech in rare dis­ease, with eyes on much big­ger in­di­ca­tions

5 years ago
R&D
First page Previous page 734735736737738739740 Next page Last page
A service from the Financial Times